Yau T, et al. Checkmate 459: a randomized, multi-center phase 3 study of nivolumab (nivo) vs sorafenib (sor) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (AHCC). Abstract LBA38_PR. ESMO Congress 2019, 28 sept. Barcelona, Spanje.
Tumor-spill tijdens coloscopie mogelijke oorzaak metachroon CRC
nov 2019 | Chirurgie, Maag-darm-leveroncologie